tirzepatide cardiovascular Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

Tirzepatide goes beyond weight loss—supporting heart health, vascular function, and overall metabolic wellness. #Tirzepatide #HeartHealth #MetabolicSupport #Type2Diabetes #CardiovascularHealth #AmaneciaHealth

21.30

★★★★☆4.8 (126)

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

25.71

★★★★★4.9 (98)

CARDIOVASCULAR EFFICACY OF TIRZEPATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF 8 RANDOMIZED CLINICAL TRIALS

27.36

★★★★★5.0 (157)

Cardiovascular Outcomes with Tirzepatide Compared with Dulaglutide in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

25.20

★★★★★4.7 (84)

❇️ Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes 🟠BACKGROUND Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on

27.40

★★★★★4.9 (203)

Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year SURMOUNT‐1 trial - Hankosky

24.23

★★★★★5.0 (176)

Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice

22.62

★★★★★4.8 (132)